- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Sharp Therapeutics Corp (2): Sharp Therapeutics closes first tranche of financing | 3 | Stockwatch | ||
| Fr | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering | 419 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that... ► Artikel lesen | |
| 03.02. | Sharp Therapeutics Corp (2): Sharp arranges $3-million (U.S.) note offering | 1 | Stockwatch | ||
| 02.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes | 276 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms... ► Artikel lesen | |
| 27.01. | Sharp Therapeutics Corp (2): Sharp Therapeutics appoints Ely to advisory board | 2 | Stockwatch | ||
| 27.01. | Gaucher disease expert Robin Ely joins Sharp Therapeutics advisory board | 2 | Investing.com | ||
| 19.12.25 | Sharp Therapeutics announces $10M non-brokered private placement | 2 | Seeking Alpha | ||
| 19.12.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options | 548 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that... ► Artikel lesen | |
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update | 342 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed... ► Artikel lesen | |
| 14.10.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Arranges Non-Brokered Private Placement | 357 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it... ► Artikel lesen | |
| 08.10.25 | Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 29.08.25 | Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB | 439 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed... ► Artikel lesen | |
| 29.07.25 | Sharp Therapeutics Corp. Engages Rho Inc. to Help Advance Compounds into Clinical Trials for Gaucher Disease | 526 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a preclinical-stage biotechnology company developing... ► Artikel lesen | |
| 21.07.25 | Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders | 388 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small... ► Artikel lesen | |
| 22.05.25 | Sharp Therapeutics Corp. Reports First Quarter 2025 Results | 430 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| 13.05.25 | Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease | 450 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| 21.04.25 | STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp. | 420 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,875 | +0,43 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 89,00 | +2,59 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,675 | +25,62 % | Needham lowers Day One Biopharmaceuticals price target on costs | ||
| ADMA BIOLOGICS | 16,460 | -0,72 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| MODERNA | 50,26 | +17,17 % | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,46 | -4,05 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| EVOTEC | 5,652 | +6,56 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| ARCELLX | 114,29 | +0,25 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| ERASCA | 15,040 | +4,48 % | Erasca, Inc. (ERAS): A Bull Case Theory | ||
| TYRA BIOSCIENCES | 35,130 | +8,03 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,305 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| OCUGEN | 1,670 | +5,13 % | Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results | Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial-the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients-was completed. Topline Phase 3 data expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,050 | +1,81 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| IMMUNITYBIO | 7,992 | -7,20 % | Piper Sandler raises Immunitybio stock price target on revenue growth | ||
| CG ONCOLOGY | 61,72 | +6,73 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen |
Das Unternehmen SHARP THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHARP THERAPEUTICS CORP finden Sie auf Wallstreet Online.